Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change disclosed is the acquisition of Ordinary Shares by four individuals on November 5, 2012. These purchases resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA). The transaction price was 1,382.895 pence per Ordinary Share.
- Sir Andrew Witty: 41 shares
- Mr S M Bicknell: 89 shares
- Mr D S Redfern: 17 shares
- Mrs V A Whyte: 15 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director shareholdings.
Investor Verification Points
- Confirm the share price of 1,382.895 pence per Ordinary Share on November 5, 2012.
- Verify the total number of shares acquired by each named director through dividend re-investment.
- Check subsequent filings for any further changes in director shareholdings or financial performance updates for the full year 2012.